Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Elafibranor - Genfit

Drug Profile

Elafibranor - Genfit

Alternative Names: GFT-505; IPN-60190

Latest Information Update: 01 Dec 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Genfit
  • Class Anti-inflammatories; Antifibrotics; Antihyperglycaemics; Antihyperlipidaemics; Hepatoprotectants; Organic sulfur compounds; Phenyl ethers; Propionic acids; Small molecules
  • Mechanism of Action Antioxidants; Peroxisome proliferator-activated receptor alpha agonists; Peroxisome proliferator-activated receptor delta agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Primary biliary cirrhosis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Primary biliary cirrhosis
  • Discontinued Hepatic fibrosis; Lipid metabolism disorders; Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis; Type 2 diabetes mellitus

Most Recent Events

  • 27 Oct 2022 Ipsen initiates a phase I pharmacokinetic trial in (In volunteers) in France (PO, Tablet) (NCT05564208), (EudraCT2022-001883-91)
  • 03 Oct 2022 Ipsen plans a phase I trial in healthy volunteers in September 2022 (PO) (NCT05564208), (EudraCT2022-001883-91)
  • 19 Sep 2022 Ipsen initiates a phase I pharmacokinetics trial (In volunteers) in USA (PO, Tablet) (NCT05543369)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top